← Back to Search

Monoclonal Antibodies

KHK4951 for Age-Related Macular Degeneration

Phase 2
Recruiting
Research Sponsored by Kyowa Kirin, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Active subfoveal MNV (any subtype) or juxtafoveal MNV secondary to AMD with leakage affecting the fovea in the study eye at screening
Be older than 18 years old
Must not have
Subretinal hemorrhage, fibrosis, or atrophy of > 50% of the total lesion area and/or that involves the fovea in the study eye
Uncontrolled glaucoma in the study eye
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing special eye drops called KHK4951 to help people with a vision problem known as nAMD. The drops aim to improve vision by addressing abnormal blood vessels in the eye.

Who is the study for?
This trial is for adults with active neovascular Age-Related Macular Degeneration (nAMD) affecting the center of their retina. Participants must have certain levels of vision clarity and retinal thickness. Those with extensive eye damage, uncontrolled glaucoma, previous significant eye surgeries or treatments, or other conditions that could affect vision outcomes are excluded.
What is being tested?
The study is testing the effectiveness and safety of KHK4951 eye drops compared to Aflibercept injections in treating nAMD. The goal is to see if KHK4951 can improve visual function and reduce abnormal blood vessel growth under the retina.
What are the potential side effects?
While specific side effects for KHK4951 aren't listed, similar treatments often cause eye irritation, redness, discomfort at the injection site (for Aflibercept), potential increase in intraocular pressure, and rarely infection or inflammation inside the eye.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My eye condition is due to AMD and affects the center of my vision.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
More than half of the lesion in my eye involves bleeding, scarring, or tissue loss and affects the central vision area.
Select...
My glaucoma in one eye is not under control.
Select...
I have active inflammation in my eye.
Select...
My vision loss won't improve even if the swelling in my eye is treated.
Select...
I have no eye conditions affecting my central vision other than nAMD.
Select...
I have used corticosteroids around or in my eye.
Select...
I have had laser treatment on my macula.
Select...
I have been treated with IVT anti-VEGF drugs before.
Select...
I have never had an eye infection called endophthalmitis.
Select...
I have had uveitis without a known cause or due to an autoimmune condition.
Select...
I have had eye surgery for AMD.
Select...
I have had treatments like Visudyne, radiation, or laser therapy for my eye condition.
Select...
I do not have an active eye infection.
Select...
I have had a retinal detachment in the eye being studied.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Arm CExperimental Treatment2 Interventions
KHK4951 Low dose
Group II: Arm BExperimental Treatment2 Interventions
KHK4951 Middle dose
Group III: Arm AExperimental Treatment2 Interventions
KHK4951 High dose
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Aflibercept Injection
2019
Completed Phase 4
~180

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Age-Related Macular Degeneration (AMD) are anti-VEGF agents, which inhibit the action of vascular endothelial growth factor (VEGF). VEGF is a protein that stimulates the growth of abnormal blood vessels in the retina, leading to fluid leakage, hemorrhage, and scar tissue formation. By blocking VEGF, these treatments reduce these harmful effects, thereby preserving vision and preventing further deterioration. This is crucial for AMD patients as it helps maintain their visual function and quality of life, allowing them to perform daily activities with greater independence.

Find a Location

Who is running the clinical trial?

Kyowa Kirin, Inc.Lead Sponsor
48 Previous Clinical Trials
5,565 Total Patients Enrolled
Shinsaku KiharaStudy DirectorKyowa Kirin Co., Ltd.
1 Previous Clinical Trials
150 Total Patients Enrolled
Sotaro TakigawaStudy DirectorKyowa Kirin Co., Ltd.
1 Previous Clinical Trials
150 Total Patients Enrolled
~86 spots leftby Nov 2025